Shots:
- UCB has entered into a definitive agreement to acquire Neurona Therapeutics for up to $1.15B, including $650M upfront and up to $500M in potential milestones expected to close by end of Q2’26
- The acquisition adds NRTX-1001, an investigational neuronal cell therapy currently in P-I/II study for drug-resistant mesial temporal lobe epilepsy, strengthening UCB’s neuroscience pipeline
- NRTX-1001 has received RMAT designation from the US FDA for drug‑resistant mesial temporal lobe epilepsy (MTLE) and PRIME designation from the EMA for adults with drug‑resistant focal epilepsy, highlighting its potential as a disease-modifying, single-dose regenerative therapy for epilepsy
Ref: UCB | Image: UCB | Press Release
Related News: UCB Reports P-III (BE BOLD) Trial Results on Bimzelx (Bimekizumab) in Active Psoriatic Arthritis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
